India's JB Chem and Pharma posts higher quarterly profit on steady domestic demand

J B Chemicals and Pharmaceuticals

14/05/2025 15:36

May 14 (Reuters) - Indian drugmaker JB Chemicals and Pharmaceuticals JBCH.NS on Wednesday reported higher fourth-quarter profit, driven by sustained domestic demand for its drugs that treat gastrointestinal conditions.

The company, which makes the 'Rantac' antacid, reported consolidated net profit of 1.46 billion Indian rupees ($17.10 million) for the quarter ended March 31, compared with 1.26 billion rupees a year earlier.

Analysts on average expected quarterly profit of 1.45 billion rupees, according to data compiled by LSEG.

The drugmaker's overall revenue climbed 10% to 9.49 billion rupees in the fourth quarter.

KEY CONTEXT

Along with the steady market for its gastrointestinal medicines, Metrogyl and Sporlac, the company also benefitted from the demand for its drugs that treat chronic conditions such as hypertension.

Quarterly revenue from its India business, its biggest, rose 11% to 5.19 billion rupees and accounted for 55% of the total.

A 9% climb in JB Pharma's contract drug manufacturing business also aided its fourth-quarter results.

PEER COMPARISON

Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
Div yield (%)
J B Chemicals and Pharmaceuticals Ltd
JBCH.NS
30.38
19.17
12.65
20.57
Buy
11
0.74
0.79
Torrent Pharmaceuticals Ltd
TORP.NS
42.78
25.05
13.04
31.09
Hold
24
0.92
0.99
Mankind Pharma Ltd
MNKI.NS
45.60
23.69
22.14
15.14
Buy
13
0.90
NULL
Abbott India Ltd
ABOT.NS
40.52
31.75
7.38
12.64
Strong Buy
5
0.90
1.36

* The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

JANUARY TO MARCH STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 85.3840 Indian rupees

JBCH v Peers https://tmsnrt.rs/3F6FZp1

 (Reporting by Kashish Tandon in Bengaluru; Editing by Shreya Biswas)

 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))